SCHEMBL516396

SCHEMBL516396

COC(=O)c1ccc(C=O)cn1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.61
ALDH1A1 P00352 5/20 0.55
KDM4E B2RXH2 3/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
LCK P06239 1/20 0.42
PARP1 P09874 1/20 0.41
P4HTM Q9NXG6 1/20 0.41
CYP1A2 P05177 2/20 0.41
MAPT P10636 2/20 0.41
HPGD P15428 2/20 0.41
CYP2C19 P33261 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
HSP90AA1 P07900 1/20 0.41
CYP2C9 P11712 1/20 0.41
GABRP O00591 2/20 0.40
GABRD O14764 2/20 0.40
GABRA1 P14867 2/20 0.40
GABRB1 P18505 2/20 0.40
GABRG2 P18507 2/20 0.40
GABRB3 P28472 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24975190 0.87 MAPK1 (0.54) MAPK1ALDH1A1KDM4EL3MBTL1LCK
SCHEMBL20764288 0.86 KDM4E (0.58) MAPK1ALDH1A1KDM4EL3MBTL1LMNA
SCHEMBL3242056 0.84 MAPK1 (0.59) MAPK1ALDH1A1KDM4EL3MBTL1LCK
SCHEMBL5191169 0.83 GABRA1 (0.50) MAPK1ALDH1A1KDM4ECYP1A2MAPT
SCHEMBL20419401 0.81 MAPK1 (0.56) MAPK1ALDH1A1KDM4EL3MBTL1LCK
SCHEMBL10165326 0.81 GABRG2 (0.44) MAPK1ALDH1A1KDM4EP4HTMGABRP
SCHEMBL9005408 0.80 MAPK1 (0.54) MAPK1ALDH1A1KDM4EL3MBTL1LCK
SCHEMBL19304182 0.80 P4HTM (0.69) MAPK1ALDH1A1KDM4EL3MBTL1P4HTM
SCHEMBL22046801 0.79 P4HTM (0.44) MAPK1ALDH1A1KDM4EL3MBTL1P4HTM
SCHEMBL20419398 0.79 MAPK1 (0.53) MAPK1ALDH1A1KDM4EL3MBTL1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4741386-A1 PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2026-05-13 EP disclosed
EP-4694981-A1 HETEROCYCLIC COMPOUNDS AS DUAL INHIBITORS OF PD-L1 AND ADENOSINE RECEPTORS Aurigene Oncology Limited (IN) 2026-02-18 EP disclosed
EP-4658656-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES Beone Medicines I GmbH (CH) 2025-12-10 EP disclosed
US-20250346597-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES BEONE MEDICINES I GMBH (CH) 2025-11-13 US disclosed
US-20250289799-A1 PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF JIANGSU YAHONG MEDITECH CO., LTD. (CN) 2025-09-18 US disclosed
US-12358929-B2 NMDA receptor modulators and uses thereof NOVARTIS AG (CH) 2025-07-15 US disclosed
US-20250171459-A1 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMA (US) 2025-05-29 US disclosed
WO-2025095751-A1 NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER COMPRISING SAME 현대약품 주식회사 2025-05-08 WO disclosed
US-20250074904-A1 NSD2-TARGETED CHECMICAL DEGRADERTS AND COMPOSITIONS AND METHODS OF USE THEREOF THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 2025-03-06 US disclosed
EP-4516779-A1 PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2025-03-05 EP disclosed
US-20120027692-A1 PYRROLOPYRIMIDINEDIONE AND ITS THERAPEUTIC USE CHIESI FARMACEUTICI S.P.A. (IT) 2012-02-02 US disclosed
US-20120027692-A1 PYRROLOPYRIMIDINEDIONE AND ITS THERAPEUTIC USE CHIESI FARMACEUTICI S.P.A. (IT) 2012-02-02 US disclosed
EP-2391629-A1 DIMERIC PYRROLOPYRIMIDINEDIONE AND ITS USE IN THERAPY OF RESPIRATORY DISEASES CHIESI FARMACEUTICI S.p.A. (IT) 2011-12-07 EP disclosed
WO-2011127933-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2011-10-20 WO disclosed
WO-2011067272-A1 INSECTICIDAL COMPOUNDS BASED ON ISOXAZOLINE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2011-06-09 WO disclosed
WO-2010086638-A1 DIMERIC PYRROLOPYRIMIDINEDIONE AND ITS USE IN THERAPY OF RESPIRATORY DISEASES PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) 2010-08-05 WO disclosed
WO-2010086638-A1 DIMERIC PYRROLOPYRIMIDINEDIONE AND ITS USE IN THERAPY OF RESPIRATORY DISEASES PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) 2010-08-05 WO disclosed
EP-0733033-B1 PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS ZENECA LTD (GB) 1999-12-22 EP disclosed
US-5811459-A PAIN RELIEVERS ZENECA LIMITED (GB) 1998-09-22 US disclosed
EP-0733033-A1 PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS ZENECA LIMITED (GB) 1996-09-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120027692-A1 PYRROLOPYRIMIDINEDIONE AND ITS THERAPEUTIC USE SERPINB1, ELANE, MPO MAPK1 2821/4885ALDH1A1 560/4885KDM4E 4280/4885
US-20250074904-A1 NSD2-TARGETED CHECMICAL DEGRADERTS AND COMPOSITIONS AND METHODS OF USE THEREOF NCOR2, NSD2, NCOR1 MAPK1 4583/4885ALDH1A1 4559/4885KDM4E 486/4885
US-20250171459-A1 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME APOL1, PDXK, PNLIP MAPK1 2043/4885ALDH1A1 3122/4885KDM4E 3628/4885
US-12358929-B2 NMDA receptor modulators and uses thereof GRIN1, GRIN2A, GRIN2C MAPK1 3035/4885ALDH1A1 2036/4885KDM4E 1415/4885
US-20250346597-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES DGKG, DGKA, DGKK MAPK1 392/4885ALDH1A1 4075/4885KDM4E 2066/4885
US-20250289799-A1 PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF USP1, UPP1, UFL1 MAPK1 1780/4885ALDH1A1 336/4885KDM4E 1951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.